Objective To investigate the clinical effect of Sacubitril Valsartan in the treatment of patients with chronic heart failure and its effect on cardiac function.Methods The clinical data of 80 patients with chronic heart failure admitted to the People′s Hospital of Gaozhou from August 2019 to May 2020 were retrospectively analyzed,and they were divided into observation group(40 cases)and control group(40 cases)according to treatment methods.The control group was treated with Metoprolol Sustained-Release Tablets,and the observation group was treated with Sacubitril Valsartan.The clinical efficacy,cardiac function indexes,serum hypersensitive troponin(hs-TnT)and N-terminus brain natriuretic peptide precursor(NT-proBNP)before and after treatment were compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group(72.50%),the difference was statistically significant(P＜0.05).After treatment,left ventricular end-diastolic diameter(LVEDD),left atrial diameter(LA)of the two groups were lower than those before treatment,while left ventricular ejection fraction(LVEF)of the two groups was higher than that before treatment,LVEDD and LA of the observation group were lower than those of the control group,while LVEF of the observation group was higher than that in the control group,the differences were statistically significant(P＜0.05).After treatment,the levels of hs-TNT and NT-Pro BnP in both groups were lower than those before treatment,and the observation group was lower than that in the control group,the differences were statistically significant(P＜0.05).Conclusion Compared with conventional treatment methods,Sacubitril Valsartan in clinical treatment of chronic heart failure has better cardiac function improvement,which is worthy of clinical promotion and application.